CLINICAL EFFICACY AND SAFETY OF THE COMBINATION OF ROSUVASTATIN AND EZETIMIBE IN THE TREATMENT OF DYSLIPIDEMIA
Keywords:
Rosuvastatin, ezetimibe, dyslipidemia, LDL cholesterol, cardiovascular outcomes, safety profile.Abstract
This article analyzes the clinical efficacy and safety of the combination of rosuvastatin and ezetimibe in the treatment of dyslipidemia. Dyslipidemia is a major risk factor for cardiovascular disease, and while statins are first-line therapy for lowering LDL cholesterol, monotherapy may be insufficient in some patients. Clinical studies demonstrate that the combination therapy provides greater LDL cholesterol reduction compared to monotherapy, with a safety profile similar to statins alone.
References
1.
Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. NEJM. 2015;372(25):2387–2397.
2.
Kim BK, Hong SJ, Lee YJ, et al. Rosuvastatin plus Ezetimibe versus High-Intensity Statin Monotherapy in Patients with Coronary Artery Disease (RACING trial). The Lancet. 2022;399(10338):2061–2073.
3.
Ballantyne CM, Blazing MA, King TR, Brady WE, Palmisano J. Efficacy and Safety of Ezetimibe Co-Administered with Statins. Current Atherosclerosis Reports. 2004;6(5):379–385.
4.
Kosoglou T, Statkevich P, Johnson-Levonas AO, Paolini JF, Bergman AJ, Alton KB. Ezetimibe: A Review of its Metabolism, Pharmacokinetics and Drug Interactions. Clinical Pharmacokinetics. 2005;44(5):467–494.
5.
Stone NJ, Robinson JG, Lichtenstein AH, et al. 2018 ACC/AHA Guideline on the Management of Blood Cholesterol. JACC. 2019;73(24):e285–e350.
